Combined archive search across FBI Vault, SPLC, PHMPT, ACIP, NIH grants, the Federal Writers' Project, and other collections we've ingested.
George B Sigal · MESO SCALE DIAGNOSTICS, LLC · 2023 · $842,062 — Our objective is to develop better assays for measuring antibodies produced in people after influenza infection or vaccination. We’ll develop assays that measure total antibody responses, and assays that specifically measure the antibodies responsible for protection from infection. By using high-thr…
Richard John Martin · IOWA STATE UNIVERSITY · 2023 · $469,119 — Project Summary Filariases are a group of neglected tropical diseases produced by infection with microfilaria of Clade III parasitic nematodes that are transmitted by biting insects. One example is the lymphatic filariasis produced by Brugia malayi. Lymphatic filariasis is a debilitating and disfigu…
ERIC T. KOOL · STANFORD UNIVERSITY · 2023 · $623,371 — Work in the last decade from many labs has underlined the critical importance of RNA-mediated cellular pathways, and clear connections of specific RNAs to human health. RNAs are increasingly viewed both as appealing therapeutic targets, and as therapeutic agents themselves. We hypothesize that obtai…
STEVEN GREGORY REED · HDT BIO CORPORATION · 2023 · $538,074 — PROJECT SUMMARY/ABSTRACT Our team - in collaboration with other vaccine developers - has been actively involved in tuberculosis (TB) vaccine discovery for the past three decades and led the team that developed the M72 vaccine that has provided proof of concept for effective subunit TB vaccines. Obst…
Javeed Ali Shah · UNIVERSITY OF WASHINGTON · 2023 · $256,475 — Project Summary/Abstract. Over one million people died from tuberculosis in 2021. Current treatments are long, costly, and often induce severe adverse effects, but the current vaccine has not been improved in over 100 years. Improved understanding of the host factors that influence Mtb pathogenesis …
RONALD LEVY · STANFORD UNIVERSITY · 2023 · $514,997 — Project Summary: Cancer is a leading global cause of mortality. The goal of this multi-disciplinary project is to pre-clinically advance a novel concept for selective and efficient mRNA delivery that enables a highly promising vaccination strategy for cancer immunotherapy. Given the potential of can…
Parisa Yousefpour · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · 2023 · $73,772 — PROJECT SUMMARY Infectious diseases such as HIV, malaria, tuberculosis, and seasonal influenza epidemics and emergence of new pandemics remain major global health problems highlighting the need for innovative approaches in vaccine design. The precise kinetics of antigen exposure relative to inflamma…
Elena Vassilieva · EMORY UNIVERSITY · 2023 · $195,625 — PROJECT SUMMARY Severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2) is currently causing the coronavirus disease (COVID-19) in pandemic proportion. According to John Hopkins university data tracker, there were 120,217,175 global cases and 2,660,456 deaths worldwide on March 15, 2021. The d…
James D. Bryers · UNIVERSITY OF WASHINGTON · 2023 · $540,184 — While Staphylococcus aureus (SA) commonly asymptomatically colonizes the skin and nose of healthy humans, severe disease can result from infection of the blood, bone, skin, and lungs, as well as sites of catheters and prosthetic devices. With currently approved therapy, about one-third of patients d…
Rajesh Thippeshappa · TEXAS BIOMEDICAL RESEARCH INSTITUTE · 2023 · $378,000 — Abstract/Summary: Commonly used animal models of HIV-1 include infection of macaques with Simian Immunodeficiency Virus (SIV) or Simian-Human Immunodeficiency Virus (SHIV) containing HIV envelope (Env) or reverse transcriptase. These animal models have been extremely useful in understanding HIV path…
Vitaly V. Ganusov · UNIVERSITY OF TENNESSEE KNOXVILLE · 2023 · $570,739 — Research Summary Tuberculosis (TB), a disease caused by the bacteria Mycobacterium tuberculosis (Mtb), remains a major infec- tious disease of humans in the world. After the initial local infection of one site in the lung Mtb somehow dissem- inates in the lung and often spreads beyond the lung. In f…
Yamin Li · UPSTATE MEDICAL UNIVERSITY · 2023 · $81,500 — SUMMARY The mRNA-based therapeutics has wide applications in disease prevention and treatment. However, its wide practical application is largely limited by the delivery concerns. Cationic lipids are effective carrier materials for mRNA delivery and the chemical structure of lipid molecules is criti…
Sarah Elizabeth Walker · STATE UNIVERSITY OF NEW YORK AT BUFFALO · 2023 · $333,429 — SUMMARY: The level of each protein synthesized in a cell results from both the amount of mRNA available, and the number of ribosomes that initiate translation of that mRNA. Eukaryotic translation initiation factors (eIFs) can reprogram which mRNAs are available and translated to produce different le…
KENT E. KESTER · INTERNATIONAL AIDS VACCINE INITIATIVE · 2023 · $422,266 — Project Summary/Abstract Tuberculosis remains one of the top ten leading causes of death worldwide (1). Based on the most current information from WHO 2020 report, in 2019 an estimated 1.4 million people died from TB and approximately 10,000,000 fell ill (2). The COVID-19 pandemic has led to massive…
Jianxin You · UNIVERSITY OF PENNSYLVANIA · 2023 · $227,906 — Project Summary Tumor immune suppression represents a major obstacle in achieving effective cancer immunotherapy. The goal of this exploratory project is to develop a novel mRNA-lipid nanoparticle (mRNA-LNP)-based immunotherapy to overcome this challenge in pancreatic cancer, one of the deadliest ma…
Afamefuna Okoye · OREGON HEALTH & SCIENCE UNIVERSITY · 2023 · $840,477 — PROJECT SUMMARY Although the advent of combination antiretroviral therapy (cART) has dramatically improved the prognosis of people living with human immunodeficiency virus (HIV), cART alone cannot eradicate the infection and, therefore, daily treatment must be maintained for life to prevent relapse …
Daniel F. Hoft · SAINT LOUIS UNIVERSITY · 2023 · $667,594 — -γ-producing Th1 cells have been extensively studied for development of novel vaccines and therapeutics against Mycobacterium tuberculosis (Mtb) infection. However, recent studies demonstrate that Mtb-specific Th1 cells alone do not predict protection against tuberculosis (TB). Therefore, although T…
Leonidas Stamatatos · FRED HUTCHINSON CANCER CENTER · 2023 · $2,099,783 — ABSTRACT OVERALL The main goal of our IPCAVD Program grant is to evaluate in humans self-amplifying mRNA (saRNA) vaccines that express two HIV-1 Env-derived protein immunogens that activate and initiate the maturation of VRC01-class B cell receptors (BCRs). The first immunogen, 426c.Mod.Core, was sp…
Mariah A Hassert · UNIVERSITY OF IOWA · 2023 · $69,080 — PROJECT SUMMARY Seasonal influenza A (IAV) and other airborne viral pathogens such as SARS-CoV-2 represent a substantial burden on global public health. While sterilizing immunity can be attained through neutralizing antibodies, seasonal antigenic drift permits viral evasion of humoral immunity, whi…
David K Gifford · THINK THERAPEUTICS, INC. · 2024 · $306,500 — Project Summary We propose to develop a new immunogenicity assay and machine learning based framework for creating tolerization vaccines for autoimmune diseases with improved population coverage. In collaboration with Harvard University and the University of Massachusetts Chan Medical School Diabete…